FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220959947> ?p ?o ?g. }

• W4220959947 endingPage "166" @default.
• W4220959947 startingPage "154" @default.
• W4220959947 abstract "IntroductionThe RECOURSE trial demonstrated a modest benefit in overall survival (OS) for trifluridine/tipiracil (FTD/TPI) versus placebo in pretreated metastatic colorectal cancer (mCRC) patients. Unfortunately, quality of life (QoL) was not assessed. We evaluated QoL and survival of patients treated with FTD/TPI in daily practice.Patients and MethodsQUALITAS is a substudy of the Prospective Dutch CRC cohort (PLCRC). From 150 mCRC patients treated with FTD/TPI, QoL (EORTC QLQ-C30 and QLQ-CR29) was assessed monthly from study entry, and linked to clinical data of the Netherlands Cancer Registry. Joint models were constructed combining mixed effects models with Cox PH models. Primary endpoint was difference in QoL over time (which was deemed clinically relevant if ≥10 points). Secondary endpoints were progression-free survival (PFS), time to treatment failure (TTF), and OS. We analyzed the association between QLQ-C30 Summary Score (QoL-SS) at FTD/TPI initiation (baseline) and survival.ResultsThere was no clinically relevant change in QoL-SS from baseline to 10 months post-baseline (i.e. the cut-off point after which 90% of patients had discontinued FTD/TPI treatment): -5.3 [95% CI -8.7;-1.5]. Patients who were treated with FTD/TPI for ≥ 3 months (n = 85) reported 6.3 [1.6;11.1] points higher baseline QoL, compared to patients treated < 3 months (n = 65, “poor responders”). In the latter, time to a clinically relevant QoL deterioration was < 2 months. Median PFS, TTF and OS were 2.9 [2.7;3.1], 3.1 [2.9;3.2] and 7.7 [6.6;8.8] months, respectively. Worse baseline QoL-SS was independently associated with shorter OS (HR 0.45 [0.32;0.63]), PFS (0.63 [0.48;0.83]), and TTF (0.64 [0.47;0.86]).ConclusionThe maintenance of QoL during FTD/TPI treatment in daily practice supports its use. The QoL deterioration in “poor responders” is likely due to disease progression. The strong association between worse baseline QoL and shorter survival suggests that clinicians should take QoL into account when determining prognosis and treatment strategy for individual patients." @default.
• W4220959947 created "2022-04-03" @default.
• W4220959947 creator A5000314244 @default.
• W4220959947 creator A5002130583 @default.
• W4220959947 creator A5011221289 @default.
• W4220959947 creator A5014989295 @default.
• W4220959947 creator A5018004001 @default.
• W4220959947 creator A5019942881 @default.
• W4220959947 creator A5022676467 @default.
• W4220959947 creator A5024976681 @default.
• W4220959947 creator A5027402633 @default.
• W4220959947 creator A5030149872 @default.
• W4220959947 creator A5030619231 @default.
• W4220959947 creator A5031137165 @default.
• W4220959947 creator A5031300611 @default.
• W4220959947 creator A5039022390 @default.
• W4220959947 creator A5041404529 @default.
• W4220959947 creator A5041487312 @default.
• W4220959947 creator A5043942519 @default.
• W4220959947 creator A5048829633 @default.
• W4220959947 creator A5050495040 @default.
• W4220959947 creator A5050803774 @default.
• W4220959947 creator A5053630554 @default.
• W4220959947 creator A5053633329 @default.
• W4220959947 creator A5055525702 @default.
• W4220959947 creator A5061172196 @default.
• W4220959947 creator A5065928405 @default.
• W4220959947 creator A5067821269 @default.
• W4220959947 creator A5071697710 @default.
• W4220959947 creator A5072425763 @default.
• W4220959947 creator A5075869415 @default.
• W4220959947 creator A5077198705 @default.
• W4220959947 creator A5078461265 @default.
• W4220959947 creator A5083731832 @default.
• W4220959947 creator A5086589378 @default.
• W4220959947 date "2022-06-01" @default.
• W4220959947 modified "2023-09-27" @default.
• W4220959947 title "Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS)" @default.
• W4220959947 cites W1745036040 @default.
• W4220959947 cites W1846287826 @default.
• W4220959947 cites W1947168884 @default.
• W4220959947 cites W1977733462 @default.
• W4220959947 cites W2001108511 @default.
• W4220959947 cites W2002330540 @default.
• W4220959947 cites W2106340109 @default.
• W4220959947 cites W2167571044 @default.
• W4220959947 cites W2171534765 @default.
• W4220959947 cites W2195040438 @default.
• W4220959947 cites W2266520230 @default.
• W4220959947 cites W2275765857 @default.
• W4220959947 cites W242040007 @default.
• W4220959947 cites W2470575266 @default.
• W4220959947 cites W2508731920 @default.
• W4220959947 cites W2510622673 @default.
• W4220959947 cites W2518226578 @default.
• W4220959947 cites W2606845361 @default.
• W4220959947 cites W2754547251 @default.
• W4220959947 cites W2770125437 @default.
• W4220959947 cites W2770401723 @default.
• W4220959947 cites W2771737720 @default.
• W4220959947 cites W2774682757 @default.
• W4220959947 cites W2802514896 @default.
• W4220959947 cites W2889474794 @default.
• W4220959947 cites W2949229297 @default.
• W4220959947 cites W2971934329 @default.
• W4220959947 cites W2980779881 @default.
• W4220959947 cites W2998254999 @default.
• W4220959947 cites W3009385323 @default.
• W4220959947 cites W3011607805 @default.
• W4220959947 cites W3030149115 @default.
• W4220959947 cites W3079866290 @default.
• W4220959947 doi "https://doi.org/10.1016/j.clcc.2022.03.002" @default.
• W4220959947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35474007" @default.
• W4220959947 hasPublicationYear "2022" @default.
• W4220959947 type Work @default.
• W4220959947 citedByCount "3" @default.
• W4220959947 countsByYear W42209599472022 @default.
• W4220959947 countsByYear W42209599472023 @default.
• W4220959947 crossrefType "journal-article" @default.
• W4220959947 hasAuthorship W4220959947A5000314244 @default.
• W4220959947 hasAuthorship W4220959947A5002130583 @default.
• W4220959947 hasAuthorship W4220959947A5011221289 @default.
• W4220959947 hasAuthorship W4220959947A5014989295 @default.
• W4220959947 hasAuthorship W4220959947A5018004001 @default.
• W4220959947 hasAuthorship W4220959947A5019942881 @default.
• W4220959947 hasAuthorship W4220959947A5022676467 @default.
• W4220959947 hasAuthorship W4220959947A5024976681 @default.
• W4220959947 hasAuthorship W4220959947A5027402633 @default.
• W4220959947 hasAuthorship W4220959947A5030149872 @default.
• W4220959947 hasAuthorship W4220959947A5030619231 @default.
• W4220959947 hasAuthorship W4220959947A5031137165 @default.
• W4220959947 hasAuthorship W4220959947A5031300611 @default.
• W4220959947 hasAuthorship W4220959947A5039022390 @default.
• W4220959947 hasAuthorship W4220959947A5041404529 @default.
• W4220959947 hasAuthorship W4220959947A5041487312 @default.
• W4220959947 hasAuthorship W4220959947A5043942519 @default.
• W4220959947 hasAuthorship W4220959947A5048829633 @default.
• W4220959947 hasAuthorship W4220959947A5050495040 @default.

• next